Back to Search
MELVIN MEDOF, MD
MD
Rheumatology Physician
NPI: 1205856929Individual
Specialties, Licenses & Credentials
Rheumatology PhysicianPrimary
Internal Medicine — Rheumatology
Code: 207RR0500X
35-053029(OH)
Clinical Pathology/Laboratory Medicine Physician
Pathology — Clinical Pathology/Laboratory Medicine
Code: 207ZP0105X
35-053029(OH)
Research & Publications (20)
Structure-based mapping of DAF active site residues that accelerate the decay of C3 convertases.
PMID 17395591·J Biol Chem·2007
7-preclinical
The role of decay-accelerating factor as a receptor for Helicobacter pylori and a mediator of gastric inflammation.
PMID 16543227·J Biol Chem·2006
7-preclinical
Primed CD8(+) T-cell responses to allogeneic endothelial cells are controlled by local complement activation.
PMID 19563342·Am J Transplant·2009
7-preclinical
Locally produced and activated complement as a mediator of alloreactive T cells.
PMID 19482687·Front Biosci (Schol Ed)·2009
6-review
An early complement-dependent and TLR-4-independent phase in the pathogenesis of ethanol-induced liver injury in mice.
PMID 19133650·Hepatology·2009
7-preclinical
Donor deficiency of decay-accelerating factor accelerates murine T cell-mediated cardiac allograft rejection.
PMID 18802060·J Immunol·2008
7-preclinical
Locally produced C5a binds to T cell-expressed C5aR to enhance effector T-cell expansion by limiting antigen-induced apoptosis.
PMID 18567839·Blood·2008
7-preclinical
IFN-gamma and IL-17 production in experimental autoimmune encephalomyelitis depends on local APC-T cell complement production.
PMID 18424707·J Immunol·2008
7-preclinical
Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells.
PMID 18328742·Immunity·2008
7-preclinical
Decay accelerating factor can control T cell differentiation into IFN-gamma-producing effector cells via regulating local C5a-induced IL-12 production.
PMID 17947652·J Immunol·2007
7-preclinical
Anti-C5 antibody treatment ameliorates weakness in experimentally acquired myasthenia gravis.
PMID 18056404·J Immunol·2007
7-preclinical
Graft-derived complement as a mediator of transplant injury.
PMID 17764920·Curr Opin Immunol·2007
6-review
Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia.
PMID 16859686·Exp Neurol·2006
4-observational
Decay-accelerating factor modulates induction of T cell immunity.
PMID 15883171·J Exp Med·2005
7-preclinical
Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis.
PMID 14764738·J Immunol·2004
4-observational
Decay-accelerating factor deficiency increases susceptibility to dextran sulfate sodium-induced colitis: role for complement in inflammatory bowel disease.
PMID 15004190·J Immunol·2004
7-preclinical
An atomic resolution model for assembly, architecture, and function of the Dr adhesins.
PMID 15327779·Mol Cell·2004
8-other
Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis.
PMID 15380483·Exp Neurol·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 11100 EUCLID AVE
CLEVELAND, OH 44106 - Phone
- (216) 844-8500
Quick Facts
- NPI
- 1205856929
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile